GDNF and amyotrophic lateral sclerosis: This last strategy is retained in a Phase I clinical trial where the safety of neural progenitor cells secreting GDNF (CNS10-NPC-GDNF) transplantation in the spinal cord of ALS patients will be evaluated (ClinicalTrials.gov Identifier: NCT05306457).